Search | Clinical Trials Finder

Conditions: Myasthenia Gravis
Interventions: HIZENTRA ®; Drug
Lead sponsor: Mazen Dimachkie, MD; Other
Eligibility: 18 Years and older
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 4
States / cities: Phoenix, Arizona • Kansas City, Kansas • Buffalo, New York + 1 more

Conditions: Non-Hodgkin Lymphoma
Interventions: Epcoritamab, Lenalidomide, Ibrutinib, Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride [HCl], Prednisone, Polatuzumab Vedotin, CC-99282; Drug
Lead sponsor: Genmab; Industry
Eligibility: 18 Years and older
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 18
States / cities: Tucson, Arizona • New Haven, Connecticut • Newark, Delaware + 14 more

Conditions: Malignant Carcinoid Syndrome
Interventions: lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue); Drug
Lead sponsor: Ipsen; Industry
Eligibility: 18 Years and older
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: HER2-positive Breast Cancer
Interventions: Pertuzumab and Trastuzumab Fixed-Dose Combination for Subcutaneous Administration (PH FDC SC); Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 12
States / cities: Beverly Hills, California • San Francisco, California • Stanford, California + 9 more

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: aldesleukin; Biological
Lead sponsor: University of Washington; Other
Eligibility: 15 Years to 120 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1996 – 2004
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Malignant Solid Tumor, Lymphomas
Interventions: RRx-001; Drug
Lead sponsor: EpicentRx, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Non-Hodgkin Lymphoma
Interventions: Mosunetuzumab (Cohorts A-C), Mosunetuzumab (Cohorts D-E), Tocilizumab; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 320 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 39
States / cities: Mobile, Alabama • Anchorage, Alaska • Phoenix, Arizona + 34 more

Conditions: Rheumatoid Arthritis
Interventions: ISIS 104838; Drug
Lead sponsor: Ionis Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2003
U.S. locations: 26
States / cities: Birmingham, Alabama • Paradise Valley, Arizona • Los Angeles, California + 23 more

Conditions: Hidradenitis Suppurativa
Interventions: Lutikizumab, Placebo; Biological · Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 25
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Hot Springs, Arkansas + 20 more

Conditions: Advanced Solid Tumor, Cutaneous Tumor, Subcutaneous Tumor, Malignant Solid Tumor, Solid Tumor, Metastatic Solid Tumor, Metastasis to Soft Tissue, Non Small Cell Lung Cancer, Cutaneous Squamous Cell Carcinoma
Interventions: tolododekin alfa, Cemiplimab; Drug
Lead sponsor: Ankyra Therapeutics, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 4
States / cities: Bethesda, Maryland • Boston, Massachusetts • Portland, Oregon + 1 more

Conditions: Neoplasms, Deep Vein Thrombosis
Interventions: Dalteparin (Fragmin); Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2005
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Relapsed or Refractory Multiple Myeloma
Interventions: INCB001158, Daratumumab SC; Drug · Biological
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 14
States / cities: Daphne, Alabama • Tucson, Arizona • Denver, Colorado + 11 more

Conditions: Unspecified Adult Solid Tumor, Protocol Specific
Interventions: recombinant interleukin-7; Biological
Lead sponsor: National Institutes of Health Clinical Center (CC); NIH
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2011
U.S. locations: 3
States / cities: Bethesda, Maryland • Houston, Texas

Conditions: Melanoma
Interventions: Nivolumab/rHuPH20, Nivolumab; Biological
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 2
States / cities: Fort Wayne, Indiana • Knoxville, Tennessee

Conditions: Lipoma
Interventions: Cooled Sodium Chloride Injection, Warmed Sodium Chloride Injection; Drug
Lead sponsor: West Virginia University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Multiple Myeloma
Interventions: Daratumumab, Bortezomib, Lenalidomide, Dexamethasone, Melphalan, Prednisone, Carfilzomib; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 16
States / cities: Southington, Connecticut • Jacksonville, Florida • Orlando, Florida + 12 more

Conditions: Leukemia
Interventions: Bortezomib; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo, Risankizumab; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 44
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 41 more

Conditions: Recurrent or Metastatic Solid Tumors
Interventions: Trastuzumab Deruxtecan; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years and older
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Newport Beach, California • Atlanta, Georgia • Las Vegas, Nevada + 3 more

Conditions: Moderate or Severe Submental Fullness
Interventions: Deoxycholic acid injection, Placebo; Drug
Lead sponsor: Kythera Biopharmaceuticals; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 516 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2013
U.S. locations: 30
States / cities: Little Rock, Arkansas • Beverly Hills, California • Los Angeles, California + 26 more

Conditions: Cancer
Interventions: Nivolumab, Subcutaneous nivolumab combined with hyaluronidase; Drug · Combination Product
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Fort Myers, Florida

Conditions: T-Cell Peripheral Lymphoma, Gamma Delta Hepatosplenic T-Cell Lymphoma, Subcutaneous Panniculitis-Like T-Cell Lymphoma, NK T-Cell Lymphoma
Interventions: Rituximab, Etoposide, Siplizumab, Prednisone, Vincristine, Cyclophosphamide, Doxorubicin; Biological · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2020
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Head and Neck Cancer, Lung Cancer, Lymphoma
Interventions: Amifostine administered subcutaneously; Drug
Lead sponsor: Mt. Sinai Medical Center, Miami; Other
Eligibility: 18 Years and older
Enrollment: 452 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 1
States / cities: Miami Beach, Florida

Conditions: Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, Minimal Residual Disease + B-Cell Acute Lymphoblastic Leukemia
Interventions: Blinatumomab; Drug
Lead sponsor: Amgen; Industry
Eligibility: 28 Days to 4383 Days
Enrollment: 104 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Palo Alto, California • Philadelphia, Pennsylvania • Memphis, Tennessee + 1 more

Search by objective public record fields.

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic

Interleukin-2 in Treating Patients With Myelodysplastic Syndrome

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

ISIS 104838, an Inhibitor of Tumor Necrosis Factor, for Active Rheumatoid Arthritis

A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy

Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors

Outpatient Treatment Of Deep Venous Thrombosis Using Subcutaneous Dalteparin (Fragmin) In Low Risk Cancer Patients

INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma

Interleukin-7 in Treating Patients With Refractory Solid Tumors

A Study to Compare Nivolumab Administered Subcutaneously vs Intravenous in Melanoma Participants Following Complete Resection

Lipomas Treated With Subcutaneous Injections of Cooled or Warmed Sodium Chloride

A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

A Study of Subcutaneous Trastuzumab Deruxtecan in Participants With Metastatic Solid Tumors

Phase 3 Study of Deoxycholic Acid Injection (ATX-101) Versus Placebo for the Reduction of Localized Subcutaneous Fat in the Submental Area

Treatment Patterns and Characteristics of Patients Prescribed Opdivo Qvantig

Phase 1 Trial of Siplizumab and Dose-Adjusted EPOCH-Rituximab in T- and NK-Cell Lymphomas

Subcutaneous Amifostine Safety Study

A Study of Subcutaneous Blinatumomab in Children With R/R and and MRD+ B-Cell Precursor Acute Lymphoblastic Leukemia